Literature DB >> 7907272

Analysis of effector T cells against the murine syngeneic tumor MethA in mice orally administered antitumor polysaccharide SPR-901.

Y Takeda1, M Tanaka, H Miyazaki, S Takeo, K Nomoto, Y Yoshikai.   

Abstract

The growth of MethA tumor was significantly inhibited by oral administration of the alpha-glucan SPR-901 in BALB/c (+/+) mice but not in nude mice. Mice treated orally with SPR-901 exhibited an augmentation of antigen-specific resistance against rechallenge with the tumor cells. The tumor-neutralizing activity of regional lymph node cells from MethA-bearing mice against the tumor was augmented by oral administration of SPR-901. The tumor-neutralizing activity of lymph node cells from SPR-901-treated mice mainly appeared in Lyt2+ cells. Furthermore, lymphokine-activated killer activity of these cells was enhanced by administration of SPR-901. The antitumor effect of SPR-901 was abrogated in mice depleted of either L3T4+ or Lyt2+ cells, and in cyclosporin-A-treated mice. These results suggest that Lyt2+ cells are important effector cells in MethA-bearing mice orally administered SPR-901 and that functional exertion of both Lyt2+ and L3T4+ T cells is necessary for the antitumor effect of orally administered SPR-901 in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907272     DOI: 10.1007/bf01525634

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  28 in total

1.  Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.

Authors:  Z K Ballas; W Rasmussen
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

2.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.

Authors:  D E Kern; J P Klarnet; M C Jensen; P D Greenberg
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

3.  Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization.

Authors:  P Puccetti; R Bianchi; L Romani; E Cenci; M C Fioretti
Journal:  Int J Cancer       Date:  1989-02-15       Impact factor: 7.396

4.  The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.

Authors:  A Kosugi; T Yoshioka; T Suda; H Sano; Y Takahama; H Fujiwara; T Hamaoka
Journal:  J Leukoc Biol       Date:  1987-12       Impact factor: 4.962

Review 5.  Krestin (PSK).

Authors:  S Tsukagoshi; Y Hashimoto; G Fujii; H Kobayashi; K Nomoto; K Orita
Journal:  Cancer Treat Rev       Date:  1984-06       Impact factor: 12.111

6.  Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.

Authors:  T Chou; S Shu
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

7.  Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.

Authors:  M Nagarkatti; S R Clary; P S Nagarkatti
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

8.  Cooperative role of T lymphocytes and macrophages in anti-tumor activity of mice pretreated with schizophyllan (SPG).

Authors:  M Suzuki; T Arika; K Amemiya; M Fujiwara
Journal:  Jpn J Exp Med       Date:  1982-04

9.  Rejection of syngeneic tumor cells by the interaction of Lyt-1+ T lymphocytes and macrophages.

Authors:  M Mitani; T Matsumoto; K Mori; S Miake; K Himeno; K Nomoto
Journal:  J Clin Lab Immunol       Date:  1985-10

10.  Antitumor effect of PSK at a distant site: inductions of interleukin-8-like factor and macrophage chemotactic factor in murine tumor.

Authors:  T Ebina; K Murata
Journal:  Jpn J Cancer Res       Date:  1990-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.